Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03550313 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 565
- Enrollment target
NCT03550313 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 565 participants.
The verdict
NCT03550313, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 565 participants
- Enrollment target
Study Summary
This is a Phase 2, randomized, active-controlled, open-label study with a 3-arm parallel design. Healthy 2-month old infants (42 to 98 days of age) with no history of pneumococcal vaccination will be randomized in a 1:1:1 ratio to receive a 4-dose series of: multivalent pneumococcal conjugate vaccine coadministered with Prevnar 13 (Group 1); multivalent pneumococcal conjugate vaccine given 1 month after Prevnar 13 (Group 2); or Prevnar 13 with a single dose of multivalent pneumococcal conjugate vaccine (Group 3).
Interventions
- BIOLOGICAL Prevnar 13
- BIOLOGICAL Multivalent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 565 participants |
| Start Date | 2018-06-01 |
| Est. Completion | 2020-11-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03550313
The ClinicalTrials.gov registry entry for NCT03550313 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 565 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Prevnar 13 is the first listed.
NCT03550313 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03550313 about?
NCT03550313 is a clinical study titled "Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants". This is a Phase 2, randomized, active-controlled, open-label study with a 3-arm parallel design. Healthy 2-month old infants (42 to 98 days of age) with no history of pneumococcal vaccination will be randomized in a 1:1:1 ratio to receive a 4-dose series of: multivalent pneumococcal conjugate vaccin...
What is the current status of trial NCT03550313?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 565 participants. The study started on 2018-06-01. Estimated completion is 2020-11-05.
What interventions are being tested in trial NCT03550313?
The interventions under investigation include: Prevnar 13 (BIOLOGICAL), Multivalent (BIOLOGICAL).
Who is sponsoring clinical trial NCT03550313?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.